Sernova Corp SVA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if SVA is a good fit for your portfolio.
News
Trading Information
- Previous Close Price
- CAD 0.43
- Day Range
- CAD 0.42–0.45
- 52-Week Range
- CAD 0.38–1.15
- Bid/Ask
- CAD 0.44 / CAD 0.46
- Market Cap
- CAD 133.50 Mil
- Volume/Avg
- 291,510 / 138,336
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Sernova Corp is a clinical-stage company developing products for the treatment of chronic debilitating diseases. The company is engaged in the research and development of its proprietary Cell Pouch and associated technologies including immune-protected therapeutic cells. The Cell Pouch is is a scalable, implantable medical device designed to create a vascularized organ-like environment for the transplantation and engraftment of therapeutic cells, which then release proteins, hormones or other factors into the bloodstream for the long-term treatment of multiple chronic diseases such as type 1 diabetes, hypothyroid disease, and rare diseases such as hemophilia A.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 26
- Website
- https://www.sernova.com
Comparables
Valuation
|
Metric
|
SVA
|
KROS
|
CBAY
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 34.81 | 5.55 | 12.65 |
Price/Sales | — | — | 111.01 |
Price/Cash Flow | — | — | — |
Price/Earnings
SVA
KROS
CBAY
Financial Strength
|
Metric
|
SVA
|
KROS
|
CBAY
|
|---|---|---|---|
Quick Ratio | 1.17 | 13.63 | 10.70 |
Current Ratio | 1.20 | 14.25 | 10.96 |
Interest Coverage | −1,285.53 | — | −5.27 |
Quick Ratio
SVA
KROS
CBAY
Profitability
|
Metric
|
SVA
|
KROS
|
CBAY
|
|---|---|---|---|
Return on Assets (Normalized) | −115.56% | −35.62% | −30.06% |
Return on Equity (Normalized) | −168.47% | −39.15% | −51.97% |
Return on Invested Capital (Normalized) | −166.67% | −41.95% | −30.87% |
Return on Assets
SVA
KROS
CBAY
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Snwqjpqkwk | Hpzng | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Wcpngqqw | Fhwqtx | $102.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Hqtwtcc | Zwhbb | $97.8 Bil | |
MRNA
| Moderna Inc | Fjnwxxvx | Hdqp | $41.3 Bil | |
ARGX
| argenx SE ADR | Dxydztz | Lpn | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Cvbkbkzx | Jzqx | $21.0 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Ykhmxxvn | Npvbr | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Vjnryst | Pxmypv | $15.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Kydvnrfz | Gghcj | $12.5 Bil | |
INCY
| Incyte Corp | Rpghvgnn | Vdgdgn | $11.6 Bil |